MRK - ArQule up 101% premarket on Merck bid December, 09 2019 06:52 AM Merck & Company Inc. Merck (NYSE:MRK) has agreed to acquire ArQule (NASDAQ:ARQL) for $20 per share in cash, valuing the transaction at $2.7B.More news on: Merck & Co., Inc., ArQule, Inc., Healthcare stocks news, Stocks on the move, Merger & acquisition news, Read more ...